Kalorama Estimates Orphan Drug Market Will Expand 11.5% Annually Through 2017
News Apr 02, 2014
The world orphan drug market reached $61 billion in 2012, according to Kalorama Information's research. Incentives have created a thriving market, and the increasing incidence of diseases affecting the elderly will drive the market to expand at a rate of 11.5% annually through 2017. Learn about the latest developments and opportunities in this important market in their detailed report:
"The World Market for Orphan Drugs (Markets for Oncology, Hematology, Neurology, Endocrine, Metabolic and Other Drugs)".
In recent years, there has been a substantial increase in the number of drugs available to treat rare ("orphan") diseases, which are eligible for development incentives. In the U.S., a drug may be designated an orphan drug if the disease or condition for which it is indicated affects less than 200,000 Americans. Pharmaceutical companies have seen an opportunity in developing these orphan drugs with reduced regulatory costs and incentivized development.
This comprehensive report looks at market trends and provides in-depth market data for the U.S., along with estimates for the market opportunity in Europe, Japan and globally. With over 400 pages of market analysis and over 120 figures and tables, the report provides in-depth coverage of key competitors and important trends and challenges for makers of orphan drug treatments.
The following segments are discussed:
Analysis of the "Pure" Orphan Drug Market:
The world orphan drug market is difficult to determine due to variances in orphan drug status and requirements by country. Some publicized estimates of orphan drug markets include brand revenue that is not truly related to the orphan status of the drug. In The World Market for Orphan Drugs, Kalorama Information separates strictly orphan revenue from total brand revenue where necessary to provide a true picture of the pure orphan drug market opportunity.
Demographics, Costs, Regulation and Other Trends Examined:
The list of trends and factors affecting the orphan drug market remain lengthy. It is affected both by trends that affect the pharmaceutical industry as a whole and trends that specifically affect the orphan drug market:
Orphan drug pricing
Aging of the population
Increasing life expectancy
Trends in birth rates
Orphan drug incentives
Product availability by country/region
Extensive Company Coverage:
The World Market for Orphan Drugs looks extensively at what major pharmaceutical companies and smaller concerns are doing within this drug category and profiles over 45 companies. Company market share for both the US and global markets is provided. A variety of companies with both designations and designation/approvals are discussed.
Computer scientists at Carnegie Mellon University say neural networks and supervised machine learning techniques can efficiently characterize cells that have been studied using single cell RNA-sequencing (scRNA-seq). This finding could help researchers identify new cell subtypes and differentiate between healthy and diseased cells.